Top

Indian Journal of Hematology and Blood Transfusion

Published in:

01-04-2020 | Acute Myeloid Leukemia | Original Article

Expression Pattern and Prognostic Significance of EVI1 Gene in Adult Acute Myeloid Leukemia Patients with Normal Karyotype

Authors: Irena Marjanovic, Teodora Karan-Djurasevic, Tatjana Kostic, Marijana Virijevic, Nada Suvajdzic-Vukovic, Sonja Pavlovic, Natasa Tosic

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 2/2020

Abstract

According to current criteria, patients with acute myeloid leukemia with normal karyotype (AML-NK) are classified as intermediate risk patients. There is a constant need for additional molecular markers that will help in substratification into more precise prognostic groups. One of the potential new markers is Ecotropic viral integration 1 site (EVI1) transcriptional factor, whose expression is dissregulated in abnormal hematopoietic process. The purpose of this study was to examine EVI1 gene expression in 104 adult AML-NK patients and on 10 healthy bone marrow donors using real-time polymerase chain reaction method, and to evaluate association between EVI1 expression level and other molecular and clinical features, and to examine its potential influence on the prognosis of the disease. Overexpression of EVI1 gene (EVI1⁺ status) was present in 17% of patients. Increased EVI1 expression was predominantly found in patients with lower WBC count (P = 0.003) and lower bone marrow blast percentage (P = 0.005). EVI1⁺ patients had lower WT1 expression level (P = 0.041), and were negative for FLT3-ITD and NPM1 mutations (P = 0.036 and P = 0.003). Patients with EVI1⁺ status had higher complete remission rate (P = 0.047), but EVI1 expression didn’t influence overall and disease free survival. EVI1 expression status alone, cannot be used as a new marker for more precise substratification of AML-NK patients. Further investigations conducted on larger number of patients may indicate how EVI1 expression could influence the prognosis and outcome of AML-NK patients, by itself, or in the context of other molecular and clinical parameters.

Dohner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Löwenberg B, Bloomfield CD (2010) Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia. Net Blood 115:454–474. https://doi.org/10.1182/blood-2009-07-235358 CrossRef

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127:2391–2405. https://doi.org/10.1182/blood-2009-07-235358 CrossRefPubMed

Damm F, Heuser M, Morgan M, Wagner K, Görlich K, Grosshennig A, Hamwi I, Thol F, Surdziel E, Fiedler W, Lübbert M, Kanz L, Reuter C, Heil G, Delwel R, Löwenberg B, Valk PJ, Krauter J, Ganser A (2011) Integrative prognostic risk score in acute myeloid leukemia with normal karyotype. Blood 117:4561–4568. https://doi.org/10.1182/blood-2010-08-303479 CrossRefPubMed

Wieser R (2007) The oncogene and developmental regulator EVI1: expression, biochemical properties, and biological functions. Gene 396:346–357. https://doi.org/10.1016/j.gene.2007.04.012 CrossRefPubMed

van Barjesteh W, van Doorn-Khosrovani S, Erpelinck C, van Putten WL, Valk PJ, van der Poel-van de Luytgaarde S, Hack R, Slater R, Smit EM, Beverloo HB, Verhoef G, Verdonck LF, Ossenkoppele GJ, Sonneveld P, de Greef GE, Löwenberg B, Delwel R (2003) High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients. Blood 101:837–845. https://doi.org/10.1182/blood-2002-05-1459 CrossRef

Bindels EM, Havermans M, Lugthart S, Erpelinck C, Wocjtowicz E, Krivtsov AV, Rombouts E, Armstrong SA, Taskesen E, Haanstra JR, Beverloo HB, Döhner H, Hudson WA, Kersey JH, Delwel R, Kumar AR (2012) EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs. Blood 119:5838–5849. https://doi.org/10.1182/blood-2011-11-393827 CrossRefPubMedPubMedCentral

Yuasa H, Oike Y, Iwama A, Nishikata I, Sugiyama D, Perkins A, Mucenski ML, Suda T, Morishita K (2005) Oncogenic transcription factor Evi1 regulates hematopoietic stem cell proliferation through GATA-2 expression. EMBO J 24:1976–1987. https://doi.org/10.1038/sj.emboj.7600679 CrossRefPubMedPubMedCentral

Laricchia-Robbio L, Nucifora G (2008) Significant increase of self-renewal in hematopoietic cells after forced expression of EVI1. Blood Cells Mol Dis 40:141–147. https://doi.org/10.1016/j.bcmd.2007.07.012 CrossRefPubMed

Fears S, Mathieu C, Zeleznik-Le N, Huang S, Rowley JD, Nucifora G (1996) Intergenic splicing of MDS1 and EVI1 occurs in normal tissues as well as in myeloid leukemia and produces a new member of the PR domain family. Proc Natl Acad Sci USA 93:1642–1647. https://doi.org/10.1073/pnas.93.4.1642 CrossRefPubMedPubMedCentral

10.

Lugthart S, van Drunen E, van Norden Y, van Hoven A, Erpelinck CA, Valk PJ, Beverloo HB, Lowenberg B, Delwel R, van Drunen E, van Norden Y (2008) High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 111:4329–4337. https://doi.org/10.1182/blood-2007-10-119230 CrossRefPubMed

11.

Groschel S, Lugthart S, Schlenk RF, Valk PJ, Eiwen K, Goudswaard C, van Putten WJ, Kayser S, Verdonck LF, Lübbert M, Ossenkoppele GJ, Germing U, Schmidt-Wolf I, Schlegelberger B, Krauter J, Ganser A, Döhner H, Löwenberg B, Döhner K, Delwel R (2010) High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol 28:2101–2107. https://doi.org/10.1200/jco.2009.26.0646 CrossRefPubMed

12.

Groschel S, Schlenk RF, Engelmann J, Rockova V, Teleanu V, Kühn MW, Eiwen K, Erpelinck C, Havermans M, Lübbert M, Germing U, Schmidt-Wolf IG, Beverloo HB, Schuurhuis GJ, Ossenkoppele GJ, Schlegelberger B, Verdonck LF, Vellenga E, Verhoef G, Vandenberghe P, Pabst T, Bargetzi M, Krauter J, Ganser A, Valk PJ, Löwenberg B, Döhner K, Döhner H, Delwel R (2013) Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German–Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. J Clin Oncol 31:95–103. https://doi.org/10.1200/JCO.2011.41.5505 CrossRefPubMed

13.

Vazquez I, Maicas M, Cervera J, Agirre X, Marin-Béjar O, Marcotegui N, Vicente C, Lahortiga I, Gomez-Benito M, Carranza C, Valencia A, Brunet S, Lumbreras E, Prosper F, Gomez-Casares MT, Hernández-Rivas JM, Calasanz MJ, Sanz MA, Sierra J, Odero MD (2011) Down-regulation of EVI1 is associated with epigenetic alterations and good prognosis in patients with acute myeloid leukemia. Haematologica 96:1448–1456. https://doi.org/10.3324/haematol.2011.040535 CrossRefPubMedPubMedCentral

14.

Santamaria CM, Chillon MC, García-Sanz R, Perez C, Caballero MD, Ramos F, de Coca AG, Alonso JM, Giraldo P, Bernal T, Queizán JA, Rodriguez JN, Fernández-Abellan P, Barez A, Penarrubia MJ, Balanzategui A, Vidriales MB, Sarasquete ME, Alcoceba M, Diaz-Mediavilla J, San Miguel JF, Gonzalez M (2009) Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. Blood 114:148–152. https://doi.org/10.1182/blood-2008-11-187724 CrossRefPubMed

15.

Qin YZ, Zhao T, Zhu HH, Wang J, Jia JS, Lai YY, Zhao XS, Shi HX, Liu YR, Jiang H, Huang XJ, Jiang Q (2018) High EVI1 expression predicts poor outcomes in adult acute myeloid leukemia patients with intermediate cytogenetic risk receiving chemotherapy. Med Sci Monit 24:758–767. https://doi.org/10.12659/msm.905903 CrossRefPubMedPubMedCentral

16.

Haas K, Kundi M, Sperr WR, Esterbauer H, Ludwig WD, Ratei R, Koller E, Gruener H, Sauerland C, Fonatsch C, Valent P, Wieser R (2008) Expression and prognostic significance of different mRNA 5′-end variants of the oncogene EVI1 in 266 patients with de novo AML: EVI1 and MDS1/EVI1 overexpression both predict short remission duration. Genes Chromosomes Cancer 47:288–298. https://doi.org/10.1002/gcc.20532 CrossRefPubMed

17.

Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E, Delabesse E, Macintyre E, Gottardi E, Saglio G, Watzinger F, Lion T, van Dongen JJ, Hokland P, Gabert J (2003) Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)—a Europe against cancer program. Leukemia 17:2474–2486. https://doi.org/10.1038/sj.leu.2403136 CrossRefPubMed

18.

Budczies J, Klauschen F, Sinn BV, Győrffy B, Schmitt WD, Darb-Esfahani S, Denkert C (2012) Cutoff Finder: a comprehensive and straightforward Web application enabling rapid biomarker cutoff optimization. PLoS ONE 7:e51862. https://doi.org/10.1371/journal.pone.0051862 CrossRefPubMedPubMedCentral

19.

Marjanovic I, Karan-Djurasevic T, Ugrin M, Virijevic M, Vidovic A, Tomin D, Suvajdzic Vukovic N, Pavlovic S, Tosic N (2017) Use of wilms tumor 1 gene expression as a reliable marker for prognosis and minimal residual disease monitoring in acute myeloid leukemia with normal karyotype patients. Clin Lymphoma Myeloma Leuk 17:312–319. https://doi.org/10.1016/j.clml.2016.12.006 CrossRefPubMed

20.

Kiyoi H, Naoe T, Yokota S, Nakao M, Minami S, Kuriyama K, Takeshita A, Saito K, Hasegawa S, Shimodaira S, Tamura J, Shimazaki C, Matsue K, Kobayashi H, Arima N, Suzuki R, Morishita H, Saito H, Ueda R, Ohno R (1997) Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 11:1447–1452CrossRefPubMed

21.

Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, Naoe T (2001) Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97:2434–2439. https://doi.org/10.1182/blood.v97.8.2434 CrossRefPubMed

22.

Kuzmanovic M, Tosic N, Colovic N, Karan-Djurasevic T, Spasovski V, Radmilovic M, Nikcevic G, Suvajdzic-Vukovic N, Tomin D, Vidovic A, Virijevic M, Pavlovic S, Colovic M (2012) Prognostic impact of NPM1 mutations in Serbian adult patients with acute myeloid leukemia. Acta Haematol 128:203–212. https://doi.org/10.1159/000339506 CrossRefPubMed

23.

Su G, Lian X, Tan D, Tao H, Liu H, Chen S, Yin H, Wu D, Yin B (2015) Aberrant expression of ecotropic viral integration site-1 in acute myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma 56:472–479. https://doi.org/10.3109/10428194.2014.924118 CrossRefPubMed

24.

Ayoub E, Wilson MP, McGrath KE, Li AJ, Frisch BJ, Palis J, Calvi LM, Zhang Y, Perkins AS (2018) EVI1 overexpression reprograms hematopoiesis via upregulation of Spi1 transcription. Nat Commun 9:4239. https://doi.org/10.1038/s41467-018-06208-y CrossRefPubMedPubMedCentral

25.

Fenouille N, Bassil CF, Ben-Sahra I, Benajiba L, Alexe G, Ramos A, Pikman Y, Conway AS, Burgess MR, Li Q, Luciano F, Auberger P, Galinsky I, DeAngelo DJ, Stone RM, Zhang Y, Perkins AS, Shannon K, Hemann MT, Puissant A, Stegmaier K (2017) The creatine kinase pathway is a metabolic vulnerability in EVI1-positive acute myeloid leukemia. Nat Med 23:301–313. https://doi.org/10.1038/nm.4283 CrossRefPubMedPubMedCentral

26.

Eppert K, Takenaka K, Lechman ER, Waldron L, Nilsson B, van Galen P, Metzeler KH, Poeppl A, Ling V, Beyene J, Canty AJ, Danska JS, Bohlander SK, Buske C, Minden MD, Golub TR, Jurisica I, Ebert BL, Dick JE (2011) Stem cell gene expression programs influence clinical outcome in human leukemia. Nat Med 17:1086–1093. https://doi.org/10.1038/nm.2415 CrossRefPubMed

27.

Brand J, van Vliet MH, de Best L, Valk PJ, Viëtor HE, Löwenberg B, van Beers EH (2013) A standardized microarray assay for the independent gene expression markers in AML: EVI1 and BAALC. Exp Hematol Oncol 2:7. https://doi.org/10.1186/2162-3619-2-7 CrossRefPubMedPubMedCentral

28.

Yamazaki H, Suzuki M, Otsuki A, Shimizu R, Bresnick EH, Engel JD, Yamamoto M (2014) A remote GATA2 hematopoietic enhancer drives leukemogenesis in inv(3)(q21;q26) by activating EVI1 expression. Cancer Cell 25:415–427. https://doi.org/10.1016/j.ccr.2014.02.008 CrossRefPubMedPubMedCentral

29.

Arai S, Yoshimi A, Shimabe M, Ichikawa M, Nakagawa M, Imai Y, Goyama S, Kurokawa M (2011) Evi-1 is a transcriptional target of mixed-lineage leukemia oncoproteins in hematopoietic stem cells. Blood 117:6304–6314. https://doi.org/10.1182/blood-2009-07-234310 CrossRefPubMed

30.

Glass C, Wilson M, Gonzalez R, Zhang Y, Perkins AS (2014) The role of EVI1 in myeloid malignancies. Blood Cells Mol Dis 53:67–76. https://doi.org/10.1016/j.bcmd.2014.01.002 CrossRefPubMed

31.

Haferlach C, Bacher U, Grossmann V, Schindela S, Zenger M, Kohlmann A, Kern W, Haferlach T, Schnittger S (2012) Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases. Genes Chromosomes Cancer 51:1079–1085. https://doi.org/10.1002/gcc.21992 CrossRefPubMed

32.

Volkert S, Schnittger S, Zenger M, Kern W, Haferlach T, Haferlach C (2014) Amplification of EVI1 on cytogenetically cryptic double minutes as new mechanism for increased expression of EVI1. Cancer Genet 207:103–108. https://doi.org/10.1016/j.cancergen.2014.02.010 CrossRefPubMed

33.

Rockova V, Abbas S, Wouters BJ, Erpelinck CA, Beverloo HB, Delwel R, van Putten WL, Löwenberg B, Valk PJ (2011) Risk stratification of intermediate-risk acute myeloid leukemia: integrative analysis of a multitude of gene mutation and gene expression markers. Blood 118:1069–1076. https://doi.org/10.1182/blood-2011-02-334748 CrossRefPubMed

34.

Bou Samra E, Klein B, Commes T, Moreaux J (2012) Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients. Oncotarget 3:824–832. https://doi.org/10.18632/oncotarget.571 CrossRefPubMedPubMedCentral

35.

Niavarani A, Herold T, Reyal Y, Sauerland MC, Buchner T, Hiddemann W, Bohlander SK, Valk PJ, Bonnet D (2016) A 4-gene expression score associated with high levels of Wilms Tumor-1 (WT1) expression is an adverse prognostic factor in acute myeloid leukaemia. Br J Haematol 172:401–411. https://doi.org/10.1111/bjh.13836 CrossRefPubMed

Title: Expression Pattern and Prognostic Significance of EVI1 Gene in Adult Acute Myeloid Leukemia Patients with Normal Karyotype
Authors: Irena Marjanovic
Teodora Karan-Djurasevic
Tatjana Kostic
Marijana Virijevic
Nada Suvajdzic-Vukovic
Sonja Pavlovic
Natasa Tosic
Publication date: 01-04-2020
Publisher: Springer India
Keyword: Acute Myeloid Leukemia
Published in: Indian Journal of Hematology and Blood Transfusion / Issue 2/2020
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-019-01227-1

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

Flow Cytometry Based MRD and Its Impact on Survival Outcome in Children and Young Adults with ALL: A Prospective Study from a Tertiary Cancer Centre in Southern India

Combined Immature Platelet Fraction and Schistocyte Count to Differentiate Pregnancy-Associated Thrombotic Thrombocytopenic Purpura from Severe Preeclampsia/Haemolysis, Elevated Liver Enzymes, and Low Platelet Syndrome (SPE/HELLP)

Treading a Difficult Path: Granulocyte Colony Stimulating Factor Induced Mobilization of Stem Cells in Pregnancy

14–3–3ζ Regulates the Platelet Apoptosis During Storage

Systemic Mastocytosis with Associated Primary Myelofibrosis

Specific Combinations of Erythrocyte Group Antigens in Blood Donors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer